Martin Olivier, discusses how the nanobiome of vectors may impact the infectious processes of disease, highlighting his work on exosomes in sandflies and leishmaniasis.
In this exclusive piece the authors discuss the choice of peptide antigen, delivery system/adjuvant and delivery route as key factors in the development of an effective human vaccine against group A Streptococcus.
Author, Mark Woolhouse, discusses recent efforts to identify pathogens with pandemic potential and his own work on emerging viruses.
In this clinical trial focus, the authors discuss difficult-to-treat patients with autoimmune hepatitis, and the potential of additional treatment option JKB-122.
In this exclusive opinion piece, the authors discuss how a neuroattenuated varicella zoster virus (VZV) vaccine could provide promising protection against VZV infection.
Despite challenges and setbacks in the decades-long struggle to eradicate polio, effective vaccines, evidence-based policy and global cooperation have brought the world closer to achieving polio eradication than ever before.
Oral delivery of vaccines is an attractive approach but is hampered by a number of challenges. Here, the authors discuss the need to include immunostimulatory adjuvants in oral vaccines to overcome oral tolerance and elicit effector immune responses locally within the intestine.
Environmental change, and a growing and more connected population will promote vector-borne disease risk further. In this opinion piece, the authors discuss the role of climate modeling in disease prediction and epidemiology.